Johnson & Johnson Enterprise Innovation Inc. — Biomedical Watch V2

Traitements5programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Concurrent Chemo/Radiation Therapy (cCRT)The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.	Cancer	Phase 2	À vérifier	United States, Australia, Brazil, China, France, Hong Kong, Netherlands, Spain, …	À vérifier
Concurrent Chemo/Radiation Therapy (cCRT): CarboplatinThe purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.	Cancer	Phase 2	À vérifier	United States, Australia, Brazil, China, France, Hong Kong, Netherlands, Spain, …	À vérifier
Concurrent Chemo/Radiation Therapy (cCRT): PaclitaxelThe purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.	Cancer	Phase 2	À vérifier	United States, Australia, Brazil, China, France, Hong Kong, Netherlands, Spain, …	À vérifier
JNJ-90301900The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.	Cancer	Phase 2	À vérifier	United States, Australia, Brazil, China, France, Hong Kong, Netherlands, Spain, …	À vérifier
JNJ-90301900The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.	Cancer	Phase 2	À vérifier	United States, Australia, Brazil, China, France, Hong Kong, Netherlands, Spain, Turkey (Türkiye), United Kingdom	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
JNJ-90301900	Cancer	Phase 2	NCT06667908	CONVERGE — A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.